Vertex Pharmaceuticals Inc (VRTX)
471.12
-4.86
(-1.02%)
USD |
NASDAQ |
Nov 01, 16:00
471.00
-0.12
(-0.03%)
After-Hours: 20:00
Vertex Pharmaceuticals Enterprise Value: 115.80B for Nov. 1, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 01, 2024 | 115.80B |
| October 31, 2024 | 117.06B |
| October 30, 2024 | 116.82B |
| October 29, 2024 | 115.61B |
| October 28, 2024 | 117.16B |
| October 25, 2024 | 117.50B |
| October 24, 2024 | 116.01B |
| October 23, 2024 | 115.53B |
| October 22, 2024 | 116.78B |
| October 21, 2024 | 117.60B |
| October 18, 2024 | 118.87B |
| October 17, 2024 | 122.93B |
| October 16, 2024 | 119.96B |
| October 15, 2024 | 119.20B |
| October 14, 2024 | 119.34B |
| October 11, 2024 | 118.53B |
| October 10, 2024 | 117.10B |
| October 09, 2024 | 114.99B |
| October 08, 2024 | 112.66B |
| October 07, 2024 | 109.99B |
| October 04, 2024 | 111.72B |
| October 03, 2024 | 111.27B |
| October 02, 2024 | 113.48B |
| October 01, 2024 | 115.45B |
| September 30, 2024 | 114.24B |
| Date | Value |
|---|---|
| September 27, 2024 | 113.67B |
| September 26, 2024 | 113.74B |
| September 25, 2024 | 113.39B |
| September 24, 2024 | 113.70B |
| September 23, 2024 | 112.93B |
| September 20, 2024 | 114.20B |
| September 19, 2024 | 117.55B |
| September 18, 2024 | 116.59B |
| September 17, 2024 | 118.42B |
| September 16, 2024 | 120.53B |
| September 13, 2024 | 119.48B |
| September 12, 2024 | 117.75B |
| September 11, 2024 | 116.74B |
| September 10, 2024 | 115.71B |
| September 09, 2024 | 115.80B |
| September 06, 2024 | 115.00B |
| September 05, 2024 | 115.14B |
| September 04, 2024 | 117.72B |
| September 03, 2024 | 116.98B |
| August 30, 2024 | 122.19B |
| August 29, 2024 | 121.54B |
| August 28, 2024 | 120.60B |
| August 27, 2024 | 118.17B |
| August 26, 2024 | 118.77B |
| August 23, 2024 | 118.41B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
38.39B
Minimum
Oct 05 2021
124.75B
Maximum
Aug 01 2024
68.60B
Average
64.52B
Median
Jun 08 2020
Enterprise Value Benchmarks
| Eli Lilly and Co | 805.11B |
| Bristol-Myers Squibb Co | 151.89B |
| Regeneron Pharmaceuticals Inc | 84.89B |
| Sarepta Therapeutics Inc | 11.52B |
| Moderna Inc | 12.51B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -3.594B |
| Revenue (Quarterly) | 2.646B |
| Total Expenses (Quarterly) | 1.711B |
| EPS Diluted (Quarterly) | -13.92 |
| Gross Profit Margin (Quarterly) | 85.94% |
| Profit Margin (Quarterly) | -135.8% |
| Earnings Yield | -0.43% |
| Operating Earnings Yield | 3.43% |
| Normalized Earnings Yield | 2.529 |